Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a target name.
REQUEST A FREE TRIAL
Pipeline
Deals
Financings
Articles
BioCentury
|
May 1, 2020
Distillery Therapeutics
Blocking necroptosis to treat inflammatory bowel disease
Read More
BioCentury
|
Jul 10, 2019
Distillery Therapeutics
Activating RIPK3 could help treat melanoma and lung cancer
Read More
BioCentury
|
Aug 31, 2017
Targets & Mechanisms
Necroptosis strikes again
Direct evidence of necroptosis in Alzheimer's
Read More
BioCentury
|
May 12, 2016
Distillery Therapeutics
Therapeutics: Receptor-interacting serine-threonine kinase 3 (RIPK3; RIP3); tumor necrosis factor receptor 1 (TNFRSF1A; TNFR1; CD120a); HECT domain and ankyrin
Read More
BioCentury
|
Apr 28, 2016
Distillery Therapeutics
Therapeutics: Fas-associated via death domain (FADD); receptor-interacting serine-threonine kinase 3 (RIPK3; RIP3)
Read More
BioCentury
|
Apr 14, 2016
Distillery Therapeutics
Therapeutics: Receptor-interacting serine-threonine kinase 3 (RIPK3; RIP3)
Read More
BioCentury
|
Mar 3, 2016
Distillery Therapeutics
Therapeutics: Receptor-interacting serine-threonine kinase 3 (RIPK3; RIP3); mixed-lineage kinase domain-like (MLKL)
Read More
BioCentury
|
Jan 21, 2016
Distillery Therapeutics
Therapeutics: Receptor-interacting serine-threonine kinase 3 (RIPK3; RIP3); calcium calmodulin-dependent protein kinase II (CAMK2)
Read More
BioCentury
|
Feb 13, 2014
Targets & Mechanisms
A RIPping target in Gaucher's disease
Read More
BioCentury
|
Feb 6, 2014
Distillery Therapeutics
Indication: Endocrine/metabolic disease
Read More
Items per page:
10
1 - 10 of 12